Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851858 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
A Phase 2 study of Obesity and Diabetes, Type II, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 18
- Study locations
NCT06851858: Active Phase 2 study of Obesity and Diabetes, Type II, sponsored by AstraZeneca.
NCT06851858 is a Phase 2 study of Obesity and Diabetes, Type II that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 69 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06851858, a Phase 2 study of Obesity and Diabetes, Type II, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 18
- Study locations
Study Summary
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Primary Outcome
To determine whether treatment with AZD6234 is superior to placebo for weight loss at Study Week 26
Conditions Studied
Interventions
- DRUG AZD6234
- DRUG Placebo to match
Study Locations (18)
Florida
- Research Site - Doral
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Miami
- Research Site - Winter Park
Alabama
- Research Site - Birmingham
- Research Site - Mobile
Georgia
- Research Site - Canton
- Research Site - Fayetteville
Illinois
- Research Site - Chicago
- Research Site - Oak Brook
Kansas
- Research Site - Newton
Kentucky
- Research Site - Lexington
Missouri
- Research Site - Kansas City
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 2 |
What the registry record for NCT06851858 still lists
NCT06851858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which AZD6234 is the first listed.
NCT06851858 lists 18 locations in 11 states (Florida, Alabama, Georgia).
Frequently Asked Questions
What is clinical trial NCT06851858 about?
NCT06851858 is a clinical study titled "Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist". This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
What is the current status of trial NCT06851858?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2025-03-12. Estimated completion is 2026-05-27.
What conditions does trial NCT06851858 study?
This clinical trial studies the following conditions: Obesity, Diabetes, Type II, Endocrinology.
What interventions are being tested in trial NCT06851858?
The interventions under investigation include: AZD6234 (DRUG), Placebo to match (DRUG).
Who is sponsoring clinical trial NCT06851858?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06851858 being conducted?
This trial has 18 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06851858's enrollment target sits among peer trials
69 606th of 1053 higher than 444 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI